Core Insights - Olema Pharmaceuticals reported significant progress in 2024, including a new collaboration with Novartis, raising approximately $250 million, and advancing multiple clinical trials for its lead product, palazestrant [2][6]. Financial Performance - As of December 31, 2024, Olema had cash, cash equivalents, and marketable securities totaling $434.1 million, an increase from $261.8 million in 2023 [8][21]. - The net loss for Q4 2024 was $33.6 million, compared to $26.8 million in Q4 2023, while the total net loss for the year was $129.5 million, up from $96.7 million in 2023 [9][22]. - GAAP research and development (R&D) expenses for Q4 2024 were $32.3 million, compared to $25.9 million in Q4 2023, with total R&D expenses for the year at $124.5 million, up from $86.1 million in 2023 [10][22]. Clinical Development - The pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with second- and third-line ER+/HER2- metastatic breast cancer is on track for top-line data in 2026 [5]. - The OPERA-02 trial, evaluating palazestrant in combination with ribociclib in frontline metastatic breast cancer, is set to initiate in 2025, enabled by the Novartis collaboration and the recent equity private placement [5][6]. - The Phase 1 trial for OP-3136 was initiated before the end of 2024, with patient enrollment currently ongoing [5][6]. Research and Development Highlights - Olema presented updated clinical results for palazestrant in combination with ribociclib at major conferences, demonstrating promising efficacy in ER+/HER2- advanced or metastatic breast cancer [6]. - New preclinical data showed anti-tumor activity for palazestrant in combination with other agents, further supporting its therapeutic potential [6][15]. Strategic Partnerships - The collaboration with Novartis includes a clinical trial agreement and supply agreement, enhancing Olema's capabilities in developing treatments for metastatic breast cancer [6][14].

SAN FRANCISCO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025 at 10:30 a.m. ET. A live webcast of the presentation a ...

Core Insights - Olema Pharmaceuticals has appointed Shawnte M. Mitchell as Chief Legal Officer and Corporate Secretary, bringing extensive experience in the biotechnology industry [1][2] - The company is focused on advancing its late-stage palazestrant programs and OP-3136 KAT6 program through clinical development [2][3] - Olema is committed to transforming the standard of care for breast cancer patients with a pipeline of novel therapies [3] Company Overview - Olema Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of targeted therapies for breast cancer and other conditions [1][3] - The lead product candidate, palazestrant (OP-1250), is currently in a Phase 3 clinical trial called OPERA-01, and the company is also developing a potent KAT6 inhibitor (OP-3136) [3] Leadership Background - Shawnte M. Mitchell has 20 years of experience in the healthcare and life sciences sectors, previously serving as Chief Legal Officer at Genomatica and holding senior legal positions at Zogenix and Aptevo Therapeutics [2] - Ms. Mitchell's expertise includes regulatory, commercial, intellectual property, and business development matters, which will support Olema's strategic priorities [2]

SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that it will present new data from the Phase 1b/2 clinical study of palazestrant (OP-1250) in combination with CDK4/6 inhibitor ribociclib at the San Antonio Breast Cancer Symposium (SABCS 2024) being held December 10- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-39712 OLEMA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) De ...

Financial Reporting and Disclosure - Olema Pharmaceuticals reported financial results for the quarter ended September 30, 2024 [5] - The press release detailing the financial results was dated November 12, 2024 [4] - The financial results are included in Exhibit 99.1, which is incorporated by reference [5] - The information in Item 2.02, including the press release, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 [6] Executive Signatory - The report was signed by Shane Kovacs, Chief Operating and Financial Officer, on November 12, 2024 [8]

Presented compelling new preclinical data demonstrating anti-tumor activity for OP-3136, a novel KAT6 inhibitor, with enhanced activity of palazestrant combinations at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024) New clinical data for palazestrant (OP-1250) in combination with ribociclib to be presented at the San Antonio Breast Cancer Symposium (SABCS) in DecemberIND submission for OP-3136 expected before year end; clinical study to initiate early 2025Cash, cash equivale ...

SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that its management team will participate in the following upcoming investor conferences: Jefferies London Healthcare ConferenceDate: Wednesday, November 20, 2024, at 1:30 p.m. GMT (8:30 a.m. ET)Location: London, UKForma ...

OP-3136, a potent KAT6 inhibitor, demonstrated robust anti-tumor activity as a single agent, as well as synergy and enhanced anti-tumor activity in combination with palazestrant; IND submission expected before year endPalazestrant demonstrated combinability and enhanced tumor suppression with both everolimus and capivasertib SAN FRANCISCO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the disco ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File Number: 001-39712 OLEMA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delawar ...